Skip to main content

Advertisement

SpringerLink
Log in

Review and Perspectives of the Recent International Guidelines on Treatment of Chronic Urticaria

  • Urticaria and Atopic Dermatitis (M Furue and T Nakahara, Section Editors)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Abstract

Purpose of review

Management of urticaria can be challenging, and various guidelines have been published by national and international societies. The most recent set of international guidelines, the EAACI/GA2LEN/EDF/WAO guideline, seeks to define and classify urticaria as well as recommend diagnostic and therapeutic approaches in common subtypes of urticaria. This review aims to summarize treatment recommendations and provide additional perspectives on these recommendations.

Recent findings

The EAACI/GA2LEN/EDF/WAO guideline recommends a four-step approach to treatment of chronic urticaria: (1) second-generation antihistamines, (2) increase second-generation antihistamine up to fourfold, (3) add omalizumab, and (4) add cyclosporine. While cyclosporine has been determined to be effective in a recent meta-analysis, a careful analysis of the evidence indicates low-quality evidence.

Summary

The most recent version of the EAACI/GA2LEN/EDF/WAO guideline outlines definitions as well as diagnostic and treatment strategies for urticaria and its subtypes. While all of the recommendations are not agreed upon by all international allergy societies, there are many areas of consensus. Omalizumab is recommended before cyclosporine in the treatment algorithm. More studies are needed to provide further guidance with respect to alternative urticaria treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Zuberbier, T., W. Aberer, R. Asero, A.H. Abdul Latiff, D. Baker, B. Ballmer-Weber, et al., The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy. 2018;73:1393–1414. This is the most recent evidence and consensus based International Guideline on urticaria.

  2. Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic urticaria: a focus on pathogenesis. F1000Res. 2017;6:1095.

    Article  Google Scholar 

  3. Sanchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5(11):125–47.

    Article  Google Scholar 

  4. Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547–65.

    Article  CAS  Google Scholar 

  5. Chow SK. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy. 2012;2(2):149–60.

    Article  Google Scholar 

  6. Maspero, J., H. Cabrera, L. Ardusso, M. De Gennaro, R. Fernandez Bussy, J. Galimany, et al., [Argentine guidelines for urticaria and angioedema]. Medicina (B Aires), 2014. 74 Suppl 1: p. 1–53.

  7. Chung WH, Chu CY, Huang YH, Wang WM, Yang CH, Tsai TF. Taiwanese Dermatological Association consensus for the definition, classification, diagnosis, and management of urticaria. J Formos Med Assoc. 2016;115(11):968–80.

    Article  Google Scholar 

  8. Hide M, Hiragun T. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int. 2012;61(4):517–27.

    Article  Google Scholar 

  9. Godse K, De A, Zawar V, Shah B, Girdhar M, Rajagopalan M, et al. Consensus statement for the diagnosis and treatment of urticaria: a 2017 update. Indian J Dermatol. 2018;63(1):2–15.

    Article  Google Scholar 

  10. Zuberbier T, Greaves MW, Juhlin L, Merk H, Stingl G, Henz BM. Management of urticaria: a consensus report. J Investig Dermatol Symp Proc. 2001;6(2):128–31.

    Article  CAS  Google Scholar 

  11. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006;61(3):316–20.

    Article  CAS  Google Scholar 

  12. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64(10):1417–26.

    Article  CAS  Google Scholar 

  13. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.

    Article  CAS  Google Scholar 

  14. Weller K, Ardelean E, Scholz E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013;93(2):168–74.

    Article  CAS  Google Scholar 

  15. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676–82.

    Article  CAS  Google Scholar 

  16. Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–65.

    Article  CAS  Google Scholar 

  17. • van den Elzen, M.T., H. van Os-Medendorp, I. van den Brink, K. van den Hurk, O.I. Kouznetsova, A. Lokin, et al., Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy, 2017. 7: p. 4. This study investigated increasing antihistamines to higher than four-fold dosing in chronic urticaria. They found a limited increase in side effects and a substantial decrease in the need for third-line therapies.

  18. • Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474–81 This article describes response patterns to different doses of omalizumab from three pivotal chronic urticaria trials. They found that benefits of omalizumab were evident before week 4 in some cases and persisted to week 24. Use of 300 mg of omalizumab produced the best results.

    Article  CAS  Google Scholar 

  19. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol. 2002;110(3):484–8.

    Article  CAS  Google Scholar 

  20. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34(9):1401–7.

    Article  CAS  Google Scholar 

  21. Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005;297(3):134–8.

    Article  CAS  Google Scholar 

  22. Engin B, Ozdemir M, Balevi A, Mevlitoglu I. Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial. Acta Derm Venereol. 2008;88(3):247–51.

    PubMed  Google Scholar 

  23. Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol. 2010;152(4):384–9.

    Article  CAS  Google Scholar 

  24. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386–90.

    CAS  PubMed  Google Scholar 

  25. • Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–12 The omalizumab pregnancy registry, EXPECT, evaluates maternal, pregnancy, and infant outcomes after exposure to omalizumab, including incidence of congenital anomalies. Thus far, no apparent increased birth prevalence of major anomalies has been observed.

    Article  CAS  Google Scholar 

  26. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.

    Article  Google Scholar 

  27. • Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136(2):245–51. This review proposes a practical clinical approach to the patient with NSAID-induced urticaria and angioedema.

    Article  CAS  Google Scholar 

  28. Grattan CE, Francis DM, Slater NG, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339(8801):1078–80.

    Article  CAS  Google Scholar 

  29. Varghese R, Rajappa M, Chandrashekar L, Kattimani S, Archana M, Munisamy M, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria. Ann Allergy Asthma Immunol. 2016;116(4):344–8 e1.

    Article  Google Scholar 

  30. Magerl M, Pisarevskaja D, Scheufele R, Zuberbier T, Maurer M. Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy. 2010;65(1):78–83.

    Article  CAS  Google Scholar 

  31. Di Lorenzo G, Pacor ML, Mansueto P, Martinelli N, Esposito-Pellitteri M, Lo Bianco C, et al. Food-additive-induced urticaria: a survey of 838 patients with recurrent chronic idiopathic urticaria. Int Arch Allergy Immunol. 2005;138(3):235–42.

    Article  Google Scholar 

  32. Rajan JP, Simon RA, Bosso JV. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria. J Allergy Clin Immunol Pract. 2014;2(2):168–71.

    Article  Google Scholar 

  33. • Sánchez J, Zakzuk J, Cardona R. Evaluation of a guidelines-based approach to the treatment of chronic spontaneous urticaria. J Allergy Clin Immunology Pract. 2018;6(1):177–182.e1 This randomized controlled trial treated chronic urticaria patients according to the 2014 version of the International Guideline and found a high rate of disease control.

    Article  Google Scholar 

  34. Zuberbier T, Bernstein JA. A comparison of the United States and international perspective on chronic urticaria guidelines. The Journal of Allergy and Clinical Immunology: In Practice; 2018;6:1144–51

    Article  Google Scholar 

  35. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–7.

    Article  Google Scholar 

  36. Hawro, T., T. Ohanyan, N. Schoepke, M. Metz, A. Peveling-Oberhag, P. Staubach, et al., The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract, 2018;6:1185–90.

    PubMed  Google Scholar 

  37. • Casale TB, Bernstein JA, Maurer M, Saini SS, Trzaskoma B, Chen H, et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3(5):743–50.e1 This article looked at data from three pivotal omalizumab trials trials in treatment-refractory chronic urticaria patients and found safety and efficacy of omalizumab regardless of background therapy.

    Article  Google Scholar 

  38. • Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–49 This systematic review aimed to determine the strength of evidence for omalizumab efficacy and safety in treatment of chronic inducible urticarias and found a strong body of evidence to support use of omalizumab for some forms of inducible urticaria but not all.

    Article  CAS  Google Scholar 

  39. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bulbul Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75.

    Article  Google Scholar 

  40. • Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–50. This meta-analysis provides high-quality evidence for the efficacy and safety of different doses of omalizumab in patients with chronic urticaria.

    Article  CAS  Google Scholar 

  41. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–9.

    Article  CAS  Google Scholar 

  42. Maurer M, Kaplan A, Rosen K, Holden M, Iqbal A, Trzaskoma BL, et al. The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018;141(3):1138–9 e7.

    Article  Google Scholar 

  43. • Wood RA, Khan DA, Lang D, Peden D, Busse P, Carter M et al., AAAAI Response to the The EAACI/GA 2 LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria 2017 Revision. Allergy (in press), 2018. This AAAAI response to the International Guideline critiques some of the recommendations based on current evidence and U.S. expert opinion.

  44. Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017;31(6):1056–63.

    Article  CAS  Google Scholar 

  45. Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114(3):619–25.

    Article  Google Scholar 

  46. Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol. 1987;117(1):81–8.

    Article  CAS  Google Scholar 

  47. Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol. 1981;117(7):404–7.

    Article  CAS  Google Scholar 

  48. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. Eur J Clin Pharmacol. 1986;31(3):277–80.

    Article  CAS  Google Scholar 

  49. Sharpe GR, Shuster S. In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone. Br J Dermatol. 1993;129(5):575–9.

    Article  CAS  Google Scholar 

  50. Di Lorenzo G, D’Alcamo A, Rizzo M, Leto-Barone MS, Bianco CL, Ditta V, et al. Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review. J Asthma Allergy. 2008;2:9–16.

    Article  Google Scholar 

  51. •• Kulthanan K, Chaweekulrat P, Komoltri C, Hunnangkul S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586–99 This meta-analysis reviewed the efficacy and safety of cyclosporine A in chronic spontaneous urticaria. They concluded that cyclosporine A is effective at low to moderate doses, and that adverse events occur in a dose-dependent manner.

    Article  Google Scholar 

  52. Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol. 2005;52(1):145–8.

    Article  Google Scholar 

  53. Oguz Topal I, Kocaturk E, Gungor S, Durmuscan M, Sucu V, Yildirmak S. Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria? J Dermatolog Treat. 2016;27(2):163–6.

    Article  CAS  Google Scholar 

  54. • Cuervo-Pardo L, Gonzalez-Estrada A, Lang DM. Diagnostic utility of challenge procedures for physical urticaria/angioedema syndromes: a systematic review. Curr Opin Allergy Clin Immunol. 2016;16(5):511–5. This systematic review looks at the diagnostic utility of recommended office procedures for common physical urticaria/angioedema syndromes and concludes that there are limited high-quality data available to support the diagnostic utility of office challenges.

    Article  CAS  Google Scholar 

  55. Pfrommer C, Bastl R, Vieths S, Ehlers I, Henz BM, Zuberbier T. Characterization of naturally occuring pseudoallergens causing chronic urticaria. Journal of Allergy and Clinical Immunology. 1996;97(1, Part 3):367.

    Article  Google Scholar 

  56. Hollander SM, Joo SS, Wedner HJ. Factors that predict the success of cyclosporine treatment for chronic urticaria. Ann Allergy Asthma Immunol. 2011;107(6):523–8.

    Article  CAS  Google Scholar 

  57. Savic S, Marsland A, McKay D, Ardern-Jones MR, Leslie T, Somenzi O, et al. Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy Asthma Clin Immunol. 2015;11(1):21.

    Article  Google Scholar 

  58. Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55(4):705–9.

    Article  Google Scholar 

  59. Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy. 2010;65(11):1478–82.

    Article  CAS  Google Scholar 

  60. Wallace DV, Dykewicz MS. Seasonal allergic rhinitis: a focused systematic review and practice parameter update. Curr Opin Allergy Clin Immunol. 2017;17(4):286–94.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Allergy & Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8859, USA

    Shazia Lutfeali MD & David A. Khan MD

Authors
  1. Shazia Lutfeali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Khan MD.

Ethics declarations

Conflict of Interest

Shazia Lutfeali declares that she has no conflict of interest. David A. Khan declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Urticaria and Atopic Dermatitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lutfeali, S., Khan, D.A. Review and Perspectives of the Recent International Guidelines on Treatment of Chronic Urticaria. Curr Treat Options Allergy 5, 392–404 (2018). https://doi.org/10.1007/s40521-018-0184-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-018-0184-2

Keywords

Search

Navigation